Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ryan Fischer

Showing results (61-70 of 73) with videos related to

Pageof 8
Sort By:
Molecular Genetics & Genomic Medicine|March 23, 2021
Patients' and caregivers' maximum acceptable risk of death for non-curative gene therapy to treat Duchenne muscular dystrophyHolly L Peay, Ryan Fischer, Brennan Mange, et al.
Orphanet Journal of Rare Diseases|May 11, 2019
Priorities when deciding on participation in early-phase gene therapy trials for Duchenne muscular dystrophy: a best-worst scaling experiment in caregivers and adult patientsRyan S Paquin, Ryan Fischer, Carol Mansfield, et al.
Journal of Multidisciplinary Healthcare|September 3, 2024
Healthcare Stakeholder Perspectives on a Value Assessment Approach for Duchenne Muscular Dystrophy TherapiesRyan Fischer, Pat Furlong, Annie Kennedy, et al.
Hepatology (Baltimore, Md.)|January 27, 2023
Letter to the Editor: Insurance should cover vancomycin for primary sclerosing cholangitisAhmad H Ali, Cynthia W Buness, Ryan Fischer, et al.
Expert Review of Gastroenterology & Hepatology|February 20, 2026
Oral vancomycin for primary sclerosing cholangitis and associated inflammatory bowel disease - paving a path forwardJohn Grady, Kevin M Johnson, Richard Kellermayer, et al.
Journal of Neuromuscular Diseases|August 2, 2024
Clinician Perspectives of Gene Therapy as a Treatment Option for Duchenne Muscular DystrophyHeidi Cope, Ryan Fischer, Emma Heslop, et al.
European Journal of Medical Genetics|October 11, 2025
Re-evaluating acceptable risk of death from gene therapy: A threshold study among individuals with Duchenne muscular dystrophy and their caregivers in the US and UKHolly Peay, Ryan Fischer, Megan McNiff, et al.
Pediatric Research|November 14, 2022
Humoral and cellular response to the COVID-19 vaccine in immunocompromised childrenHeather A Morgans, Todd Bradley, Linda Flebbe-Rehwaldt, et al.
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|April 7, 2025
A survey of national practice patterns of HCC surveillance for patients with Fontan-associated liver disease: A call to actionMatthew R Kappus, Dempsey Hughes, Daniel R Ganger, et al.
The Lancet. Gastroenterology & Hepatology|April 26, 2024
Efficacy and safety of odevixibat in patients with Alagille syndrome (ASSERT): a phase 3, double-blind, randomised, placebo-controlled trialNadia Ovchinsky, Madeleine Aumar, Alastair Baker, et al.
Pageof 8

Showing results (61-70 of 73) with videos related to

Sort By:
Pageof 8
Molecular Genetics & Genomic Medicine|March 23, 2021
Patients' and caregivers' maximum acceptable risk of death for non-curative gene therapy to treat Duchenne muscular dystrophyHolly L Peay, Ryan Fischer, Brennan Mange, et al.
Orphanet Journal of Rare Diseases|May 11, 2019
Priorities when deciding on participation in early-phase gene therapy trials for Duchenne muscular dystrophy: a best-worst scaling experiment in caregivers and adult patientsRyan S Paquin, Ryan Fischer, Carol Mansfield, et al.
Journal of Multidisciplinary Healthcare|September 3, 2024
Healthcare Stakeholder Perspectives on a Value Assessment Approach for Duchenne Muscular Dystrophy TherapiesRyan Fischer, Pat Furlong, Annie Kennedy, et al.
Hepatology (Baltimore, Md.)|January 27, 2023
Letter to the Editor: Insurance should cover vancomycin for primary sclerosing cholangitisAhmad H Ali, Cynthia W Buness, Ryan Fischer, et al.
Expert Review of Gastroenterology & Hepatology|February 20, 2026
Oral vancomycin for primary sclerosing cholangitis and associated inflammatory bowel disease - paving a path forwardJohn Grady, Kevin M Johnson, Richard Kellermayer, et al.
Journal of Neuromuscular Diseases|August 2, 2024
Clinician Perspectives of Gene Therapy as a Treatment Option for Duchenne Muscular DystrophyHeidi Cope, Ryan Fischer, Emma Heslop, et al.
European Journal of Medical Genetics|October 11, 2025
Re-evaluating acceptable risk of death from gene therapy: A threshold study among individuals with Duchenne muscular dystrophy and their caregivers in the US and UKHolly Peay, Ryan Fischer, Megan McNiff, et al.
Pediatric Research|November 14, 2022
Humoral and cellular response to the COVID-19 vaccine in immunocompromised childrenHeather A Morgans, Todd Bradley, Linda Flebbe-Rehwaldt, et al.
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|April 7, 2025
A survey of national practice patterns of HCC surveillance for patients with Fontan-associated liver disease: A call to actionMatthew R Kappus, Dempsey Hughes, Daniel R Ganger, et al.
The Lancet. Gastroenterology & Hepatology|April 26, 2024
Efficacy and safety of odevixibat in patients with Alagille syndrome (ASSERT): a phase 3, double-blind, randomised, placebo-controlled trialNadia Ovchinsky, Madeleine Aumar, Alastair Baker, et al.
Pageof 8